Kymera Therapeutics KYMR Other long-term liabilities
Other long-term liabilities at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.
The official record: Kymera Therapeutics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's other long-term liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Kymera Therapeutics's other long-term liabilities?
- Kymera Therapeutics (KYMR) reported other long-term liabilities of $4.5K in Q4 2025.
- How has Kymera Therapeutics's other long-term liabilities changed year-over-year?
- Kymera Therapeutics's other long-term liabilities increased by 105.8% year-over-year, from -$77.5K to $4.5K.
- What is the long-term trend for Kymera Therapeutics's other long-term liabilities?
- Over 4 years (2021 to 2025), Kymera Therapeutics's other long-term liabilities has grown at a -32.4% compound annual growth rate (CAGR), from $86K to $18K.